Fluoguide raises SEK 104 million in private placement

Yesterday, LSIF participated in the accelerated bookbuilding process, which resulted in FluoGuide A/S (Nasdaq: FLUO) successfully raising SEK 104 million.
The proceeds will finance the execution of a Phase II clinical trial with FG001 in HGG in the US and a Phase II clinical trial with FG001 in head and neck cancer, as well as starting the preparation of the Phase III clinical trial in HGG.
Fluoguide has also attracted new, financially capable investors in this capital round, which we view positively.

At LSIF, we have invested more than our pro rata share in this round, which demonstrates our confidence in Fluoguide and its management.
Link to the press release from Fluoguide here